References

• Sahoo BM, Banik BK, Borah P, Jain A. Reactive oxygen species (ROS): Key components in cancer therapies. Anticancer Agents Med Chem. 2022;22(2):215-222. google scholar
• Reczek CR, Chandel NS. ROS Promotes cancer cell survival through calcium signaling. Cancer Cell. 2018;33(6):949-951. google scholar
• Schafer ZT, Grassian AR, Song L, et al. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature. 2009;461(7260):109-113. google scholar
• Weinberg F, Ramnath N, Nagrath D. Reactive oxygen species in the tumor microenvironment: An overview. Cancers (Basel). 2019;11(8). doi:10.3390/cancers11081191 google scholar
• Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov. 2013;12(12):931-947. google scholar
• Zhao RZ, Jiang S, Zhang L, Yu ZB. Mitochondrial electron trans-port chain, ROS generation and uncoupling (Review). Int J Mol Med. 2019;44(1):3-15. google scholar
• Perillo B, Di Donato M, Pezone A, et al. ROS in cancer therapy: The bright side of the moon. Exp Mol Med. 2020;52(2):192-203. google scholar
• Sena LA, Chandel NS. Physiological roles of mitochondrial re-active oxygen species. Mol Cell. 2012;48(2):158-167. google scholar
• Wiseman H, Halliwell B. Damage to DNA by reactive oxygen and nitrogen species: Role in inflammatory disease and progression to cancer. Biochem J. 1996;313 (Pt 1)(Pt 1):17-29. google scholar
• Okon IS, Zou MH. Mitochondrial ROS and cancer drug resis-tance: Implications for therapy. Pharmacol Res. 2015;100:170-174. google scholar
• Nakamura H, Takada K. Reactive oxygen species in can-cer: Current findings and future directions. Cancer Sci. 2021;112(10):3945-3952. google scholar
• Jelic MD, Mandic AD, Maricic SM, Srdjenovic BU. Oxidative stress and its role in cancer. J Cancer Res Ther. 2021;17(1):22-28. google scholar
• Ishimoto T, Nagano O, Yae T, et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell. 2011;19(3):387-400. google scholar
• Taguchi K, Motohashi H, Yamamoto M. Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolu-tion. Genes Cells. 2011;16(2):123-140. google scholar
• Kansanen E, Kuosmanen SM, Leinonen H, Levonen AL. The Keap1-Nrf2 pathway: Mechanisms of activation and dysregula-tion in cancer. Redox Biol. 2013;1(1):45-49. google scholar
• Ma Q. Role of nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol. 2013;53:401-426. google scholar
• Li W, Kong AN. Molecular mechanisms of Nrf2-mediated an-tioxidant response. Mol Carcinog. 2009;48(2):91-104. google scholar
• Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48. google scholar
• Weinstein IB, Joe A. Oncogene addiction. Cancer Res. 2008;68(9):3077-3080. doi:10.1158/0008-5472.CAN-07-3293 google scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: The next gener-ation. Cell. 2011;144(5):646-674. doi:10.1016/j.cell.2011.02.013 google scholar
• Arihara Y, Takada K, Kamihara Y, et al. Small molecule CP-31398 induces reactive oxygen species-dependent apoptosis in human multiple myeloma. Oncotarget. 2017;8(39):65889-65899. google scholar
• Nakamura H, Takada K, Arihara Y, et al. Six-transmembrane epithelial antigen of the prostate 1 protects against increased ox-idative stress via a nuclear erythroid 2-related factor pathway in colorectal cancer. Cancer Gene Ther. 2019;26(9-10):313-322. google scholar
• Shiau JP, Chuang YT, Cheng YB, et al. Impacts of oxida-tive stress and PI3K/AKT/mTOR on metabolism and the fu-ture direction of investigating fucoidan-modulated metabolism. Antioxidants (Basel). 2022;11(5). doi:10.3390/antiox11050911 google scholar
• Wen C, Wang H, Wu X, et al. ROS-mediated inactivation of the PI3K/AKT pathway is involved in the antigastric cancer effects of thioredoxin reductase-1 inhibitor chaetocin. Cell Death Dis. 2019;10(11):809. doi:10.1038/s41419-019-2035-x google scholar
• Wang Y, Qi H, Liu Y, et al. The double-edged roles of ROS in cancer prevention and therapy. Theranostics. 2021;11(10):4839-4857. google scholar
• Assi M. The differential role of reactive oxygen species in early and late stages of cancer. Am J Physiol Regul Integr Comp Physiol. 2017;313(6):R646-R653. google scholar
• Zalewska-Ziob M, Adamek B, Kasperczyk J, et al. Activity of antioxidant enzymes in the tumor and adjacent noncancerous tissues of non-small-cell lung cancer. Oxid Med Cell Longev. 2019;2901840. doi:10.1155/2019/2901840 google scholar
• Reczek CR CN. The two faces of reactive oxygen species in cancer. Annu Rev Cancer Biol. 2017;1:79-98. google scholar
• Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: Oncogene and non-oncogene addiction. Cell. 2009;136(5):823-837. google scholar
• Li Y, Zhang X, Wang Z, Li B, Zhu H. Modulation of redox homeostasis: A strategy to overcome cancer drug resistance. Front Pharmacol. 2023;14:1156538. doi:10.3389/fphar.2023.1156538 google scholar
• Aggarwal V, Tuli HS, Varol A, et al. Role of reactive oxygen species in cancer progression: Molecular mecha-nisms and recent advancements. Biomolecules. 2019;9(11). doi:10.3390/biom9110735 google scholar
• Yu G, Sun W, Shen Y, et al. PKM2 functions as a potential oncogene and is a crucial target of miR-148a and miR-326 in thyroid tumorigenesis. Am J Transl Res. 2018;10(6):1793-1801. google scholar
• Huang W, Zeng YC. A candidate for lung cancer treatment: arsenic trioxide. Clin Transl Oncol. 2019;21(9):1115-1126. google scholar
• Massaro RR, Faiao-Flores F, Rebecca VW, et al. Inhibition of proliferation and invasion in 2D and 3D models by 2-methoxyestradiol in human melanoma cells. Pharmacol Res. 2017;119:242-250. google scholar
• Karlsson JO, Kurz T, Flechsig S, Nasstrom J, Andersson RG. Superior therapeutic index of calmangafodipir in comparison to mangafodipir as a chemotherapy adjunct. Transl Oncol. 2012;5(6):492-502. google scholar
• Coriat R, Alexandre J, Nicco C, et al. Treatment of oxaliplatin-induced peripheral neuropathy by intravenous mangafodipir. J Clin Invest. 2014;124(1):262-272. google scholar
• Wang J, Ren XR, Piao H, et al. Niclosamide-induced Wnt sig-naling inhibition in colorectal cancer is mediated by autophagy. Biochem J. 2019;476(3):535-546. google scholar
• Disoma C, Zhou Y, Li S, Peng J, Xia Z. Wnt/beta-catenin signal-ing in colorectal cancer: Is therapeutic targeting even possible? Biochimie. 2022;195:39-53. google scholar
• Lotfi N, Yousefi Z, Golabi M, et al. The potential anti-cancer effects of quercetin on blood, prostate and lung cancers: An update. Front Immunol. 2023;14:1077531. doi:10.3389/fimmu.2023.1077531 google scholar
• Shafer D, Tombes MB, Shrader E, et al. Phase I trial of dimethyl fumarate, temozolomide, and radiation therapy in glioblastoma. Neurooncol Adv. 2020;2(1):vdz052. doi:10.1093/noajnl/vdz052 google scholar
• Howells LM, Iwuji COO, Irving GRB, et al. Curcumin combined with FOLFOX chemotherapy is safe and tolerable in patients with metastatic colorectal cancer in a randomized phase IIa trial. J Nutr. 2019;149(7):1133-1139. google scholar
• Talib WH, Alsalahat I, Daoud S, Abutayeh RF, Mahmod AI. Plant-derived natural products in cancer research: extraction, mecha-nism of action, and drug formulation. Molecules. 2020;25(22). doi:10.3390/molecules25225319 google scholar
• Hashem S, Ali TA, Akhtar S, et al. Targeting cancer sig-naling pathways by natural products: Exploring promising anti-cancer agents. Biomed Pharmacother. 2022;150:113054. doi:10.1016/j.biopha.2022.113054 google scholar
• Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. Curcumin: From ancient medicine to current clinical trials. Cell Mol Life Sci. 2008;65(11):1631-1652. google scholar
• Choudhari AS, Mandave PC, Deshpande M, Ranjekar P, Prakash O. Phytochemicals in cancer treatment: From preclin-ical studies to clinical practice. Front Pharmacol. 2019;10:1614. doi:10.3389/fphar.2019.01614 google scholar
• Singh S, Aggarwal BB. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane). J Biol Chem. 1995;270(42):24995-5000. google scholar
• Marin YE, Wall BA, Wang S, et al. Curcumin downregulates the constitutive activity of NF-kappaB and induces apoptosis in novel mouse melanoma cells. Melanoma Res. 2007;17(5):274-283. google scholar
• Paul S, Sa G. Curcumin as an adjuvant to cancer immunotherapy. Front Oncol. 2021;11:675923. doi:10.3389/fonc.2021.675923 google scholar
• Kim GY, Kim KH, Lee SH, et al. Curcumin inhibits immunostim-ulatory function of dendritic cells: MAPKs and translocation of NF-kappa B as potential targets. J Immunol. 2005;174(12):8116-8124. google scholar
• Giordano A, Tommonaro G. Curcumin and cancer. Nutrients. 2019;11(10). doi:10.3390/nu11102376 google scholar
• Wang H, Zhang K, Liu J, et al. Curcumin regulates cancer pro-gression: Focus on ncRNAs and molecular signaling pathways. Front Oncol. 2021;11:660712. doi:10.3389/fonc.2021.660712 google scholar
• Sadatsharifi M, Purgel M. Radical scavenger competition of alizarin and curcumin: A mechanistic DFT study on antioxidant activity. J Mol Model. 2021;27(6):166. doi:10.1007/s00894-021-04778-1 google scholar
• Jakubczyk K, Druzga A, Katarzyna J, Skonieczna-Zydecka K. Antioxidant Potential of curcumin-a meta-analysis of randomized clinical trials. Antioxidants (Basel). 2020;9(11). doi:10.3390/antiox9111092 google scholar
• Wang T, Wu X, Al Rudaisat M, Song Y, Cheng H. Cur-cumin induces G2/M arrest and triggers autophagy, ROS gen-eration and cell senescence in cervical cancer cells. J Cancer. 2020;11(22):6704-6715. google scholar
• Larasati YA, Yoneda-Kato N, Nakamae I, Yokoyama T, Meiyanto E, Kato JY. Curcumin targets multiple enzymes involved in the ROS metabolic pathway to suppress tumor cell growth. Sci Rep. 2018;8(1):2039. doi:10.1038/s41598-018-20179-6 google scholar
• Liu C, Rokavec M, Huang Z, Hermeking H. Curcumin activates a ROS/KEAP1/NRF2/miR-34a/b/c cascade to suppress colorectal cancer metastasis. Cell Death Differ. 2023;30(7):1771-1785. google scholar
• Gabr SA, Elsaed WM, Eladl MA, et al. Curcumin modulates oxidative stress, fibrosis, and apoptosis in drug-resistant cancer cell lines. Life (Basel). 2022;12(9). doi:10.3390/life12091427 google scholar
• Wang G, Duan P, Wei Z, Liu F. Curcumin sensitizes carbo-platin treatment in triple negative breast cancer through reac-tive oxygen species induced DNA repair pathway. Mol Biol Rep. 2022;49(4):3259-3270. google scholar
• Wu MF, Huang YH, Chiu LY, Cherng SH, Sheu GT, Yang TY. Curcumin induces apoptosis of chemoresistant lung cancer cells via ROS-Regulated p38 MAPK phosphorylation. Int J Mol Sci. 2022;23(15). doi:10.3390/ijms23158248 google scholar
• Dairam A, Limson JL, Watkins GM, Antunes E, Daya S. Curcum-inoids, curcumin, and demethoxycurcumin reduce lead-induced memory deficits in male Wistar rats. J Agric Food Chem. 2007;55(3):1039-1044. google scholar
• Ravindran J, Subbaraju GV, Ramani MV, Sung B, Aggar-wal BB. Bisdemethylcurcumin and structurally related his-polon analogues of curcumin exhibit enhanced prooxidant, anti-proliferative and anti-inflammatory activities in vitro. Biochem Pharmacol. 2010;79(11):1658-1666. google scholar
• Mbese Z, Khwaza V, Aderibigbe BA. Curcumin and its derivatives as potential therapeutic agents in prostate, colon and breast can-cers. Molecules. 2019;24(23). doi:10.3390/molecules24234386 google scholar
• Nakamae I, Morimoto T, Shima H, et al. Curcumin derivatives verify the essentiality of ROS upregulation in tumor suppression.Molecules. 2019;24(22). doi:10.3390/molecules24224067 google scholar
• Wang H, Xu Y, Sun J, Sui Z. The novel curcumin derivative 1g induces mitochondrial and ER-stress-dependent apoptosis in colon cancer cells by induction of ROS production. Front Oncol. 2021;11:644197. doi:10.3389/fonc.2021.644197 google scholar
• Liu X, Cui H, Li M, et al. Tumor killing by a dietary curcumin mono-carbonyl analog that works as a selective ROS genera-tor via TrxR inhibition. Eur J Med Chem. 2023;250:115191. doi:10.1016/j.ejmech.2023.115191 google scholar
• Chen M, Qian C, Jin B, et al. Curcumin analog WZ26 induces ROS and cell death via inhibition of STAT3 in cholangiocarcinoma. Cancer Biol Ther. 2023;24(1):2162807. doi:10.1080/15384047.2022.2162807 google scholar
• Feng C, Xia Y, Zou P, et al. Curcumin analog L48H37 induces apoptosis through ROS-mediated endoplasmic reticulum stress and STAT3 pathways in human lung cancer cells. Mol Carcinog. 2017;56(7):1765-1777. google scholar
• Rajamanickam V, Yan T, Wu L, et al. Allylated curcumin analog CA6 inhibits TrxR1 and leads to ROS-dependent apoptotic cell death in gastric cancer through Akt-FoxO3a. Cancer Manag Res. 2020;12:247-263. google scholar
• Zhang Z, Lin R, Liu Z, et al. Curcumin analog, WZ37, pro-motes G2/M arrest and apoptosis of HNSCC cells through Akt/mTOR inhibition. Toxicol In Vitro. 2020;65:104754. doi:10.1016/j.tiv.2019.104754 google scholar
• Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: Problems and promises. Mol Pharm. 2007;4(6):807-818. google scholar
• Heger M, van Golen RF, Broekgaarden M, Michel MC. The molecular basis for the pharmacokinetics and pharmacodynamics of curcumin and its metabolites in relation to cancer. Pharmacol Rev. 2014;66(1):222-307. google scholar
• Lao CD, Ruffin MTt, Normolle D, et al. Dose escalation of a cur-cuminoid formulation. BMC Complement Altern Med. 2006;6:10. doi:10.1186/1472-6882-6-10 google scholar
• Sandhiutami NMD, Arozal W, Louisa M, Rahmat D, Wuyung PE. Curcumin nanoparticle enhances the anticancer effect of cisplatin by inhibiting PI3K/AKT and JAK/STAT3 pathway in rat ovarian carcinoma induced by DMBA. Front Pharmacol. 2020;11:603235. doi:10.3389/fphar.2020.603235 google scholar
• Adahoun MA, Al-Akhras MH, Jaafar MS, Bououdina M. En-hanced anti-cancer and antimicrobial activities of curcumin nanoparticles. Artif Cells Nanomed Biotechnol. 2017;45(1):98-107. google scholar
• Basniwal RK, Khosla R, Jain N. Improving the anticancer ac-tivity of curcumin using nanocurcumin dispersion in water. Nutr Cancer. 2014;66(6):1015-1022. google scholar

Citations